EU–China trade understanding opens a new negotiation phase — with medical-device market access still unresolved
The European Union and China reached a preliminary trade understanding that could reduce Chinese hybrid and plug-in hybrid vehicle exports to Europe by more than half over four years. The discussions also covered improved Chinese market access for approximately €4 billion of European exports and simplified export licensing for rare earths and permanent magnets. Both sides agreed to continue negotiations on additional market-access issues, including medical devices, but no new medical-device procurement agreement was announced. Implementation details and the broader political approval process remain unresolved.
Why it matters strategically
The most interesting part for BBIU is not the automobile agreement itself.
It is the possibility that bilateral trade negotiations may alter market-access conditions in other strategically important sectors.
Medical devices are particularly relevant.
In June 2025, the European Commission introduced restrictions excluding Chinese companies from certain EU public medical-device tenders exceeding €5 million and limiting Chinese-origin devices to 50% of relevant contracts.
Those restrictions were introduced in response to barriers affecting European manufacturers seeking access to Chinese public procurement. Trade and Economic Security
The October 9 negotiations introduce the possibility of future changes to that arrangement.
But there is an important distinction:
Renewed negotiations do not mean existing restrictions have been lifted.
The strategic mechanism is:
Market-access restrictions → reciprocal negotiations → potential concessions → revised competitive conditions.
If medical-device procurement becomes part of a broader negotiated settlement, manufacturers may need to reassess their localization, distribution, and market-entry strategies.
This is also relevant to the BD tariff precedent we analyzed earlier this week.
Both developments suggest that international MedTech competition is increasingly shaped by government-negotiated market access, not merely product quality, pricing, and regulatory approval.
